Globus Medical (GMED) Q3 2025: EBITDA Margin Climbs to 35.3% as U.S. Spine and Nevro Integration Drive Upside

November 6, 2025 | By EarningsIQ Research

Globus Medical delivered a record Q3, led by a sharp EBITDA margin expansion and robust U.S. Spine growth, while Nevro integration accelerated profitability ahead of schedule. The company’s evolving capital sales strategy and focus on operational leverage underpin a raised full-year outlook, but a shift in enabling technology deal structures and ongoing integration work present new dynamics for investors to monitor into 2026.

Summary

• Margin Expansion Outpaces Expectations: Synergy capture and U.S. Spine volume drove EBITDA margin above 35% in the base business.
• Nevro Integration Turns Accretive: Margin and cash flow from Nevro improved rapidly, supporting upward guidance revision.
• Capital Model Evolves: Flexible deal structures in enabling technologies signal a pivot in revenue recognition and long-term pull-through strategy.

Performance Analysis

Globus Medical’s third quarter results showcased operational leverage and strategic execution across core business lines, with consolidated revenue growth propelled by the U.S. Spine segment and a notable turnaround in Nevro performance. The base Globus business posted 7% revenue growth, while the U.S. Spine unit outperformed at nearly 10%, marking 32 consecutive weeks of growth—a key indicator of competitive rep recruitment and broad portfolio traction. International markets, though impacted by supply prioritization and fewer selling days in Japan, delivered mid-single-digit gains, with EMEA and Asia Pacific contributing to the momentum.

Profitability metrics were the standout: Adjusted EBITDA margin for legacy Globus climbed to 35.3%, a 435 basis point improvement year over year, thanks to synergy realization, manufacturing initiatives, and favorable mix. Nevro, recently acquired, swung from a Q2 cash burn to positive free cash flow and a 16.2% EBITDA margin, well ahead of initial accretion expectations. The trauma business also notched its highest quarterly revenue, while enabling technologies saw a 27% decline, reflecting both market dynamics and a deliberate shift in sales model toward leases and pay-per-use deals.

• U.S. Spine Drives Operating Leverage: Sustained high-single-digit growth in the most profitable segment amplified margin gains.
• Nevro Outperforms on Integration: Sequential sales and margin improvement contributed to record free cash flow and a guidance raise.
• Enabling Tech Revenue Softens: Lower cash sales and increased leasing slowed top-line growth but support future implant pull-through.

Cash flow conversion was robust, with free cash flow reaching $213.9 million for the quarter, and the company continued to return capital via share repurchases, underscoring balance sheet flexibility post-NuVasive and Nevro transactions.

Executive Commentary

Strategic Positioning

1. U.S. Spine: Talent and Portfolio Depth Fuel Outperformance

Competitive rep recruitment and expansive product offerings have established U.S. Spine as the growth engine, with management emphasizing that gains are broad-based across core implants and adjacent categories. The company’s focus on attracting top sales talent and maintaining a sticky, team-based sales approach is translating into sustained share gains and above-market growth.

2. Enabling Technologies: Revenue Model Shift and Pipeline Resilience

Enabling technology revenue declined as the company increased flexibility in capital deal structures, such as leases and pay-per-use agreements. While this transition reduces immediate revenue recognition, it aligns with hospital procurement trends and is designed to support longer-term implant sales and recurring service revenue. The install base continues to drive recurring revenue, and management remains confident in the pipeline, despite near-term headwinds.

3. Nevro Integration: Early Synergy and Margin Accretion

Nevro’s integration has moved faster than anticipated, delivering positive EBITDA margin and free cash flow within two quarters post-acquisition. Cost actions have focused on R&D rationalization and SG&A reduction, with further manufacturing and sales force optimization expected to drive additional margin improvement. The platform offers future product expansion potential in pain management and adjacent indications.

4. International and Trauma: Portfolio Breadth and Supply Chain Execution

International growth was steady, with EMEA and Asia Pacific leading, aided by improved inventory and set deliveries. The trauma segment reached critical mass, now able to bid on primary vendor contracts with over 80% portfolio parity to competitors. Manufacturing challenges have been addressed, positioning trauma for further acceleration in both U.S. and international markets.

5. Capital Allocation: Share Repurchases and Organic Investment

Capital deployment remains disciplined, balancing internal investment in R&D and manufacturing with opportunistic share repurchases. The company has repurchased $256 million in shares year-to-date, with $435 million of authorization remaining, while maintaining a debt-free balance sheet post major acquisitions.

Key Considerations

Globus Medical’s Q3 underscores the company’s ability to drive both top-line growth and margin expansion through operational discipline and strategic pivots. The interplay between evolving capital sales models and strong base business execution will be central to performance in the coming quarters.

Key Considerations:

• Sales Force Momentum: Competitive rep recruiting and retention are fueling sustainable share gains, especially in U.S. Spine.
• Shift to Flexible Capital Deals: Transition to operating leases and pay-per-use models in enabling tech will smooth near-term revenue but support long-term implant pull-through.
• Nevro Integration Trajectory: Early cost synergies and margin improvements are promising, but full-year growth durability remains to be proven as integration continues.
• International and Trauma Execution: Set delivery cadence and expanded trauma portfolio unlock new contract opportunities and growth vectors outside the U.S.
• Capital Allocation Discipline: Share repurchases and R&D investment signal management’s confidence in organic growth and value creation.

Risks

Enabling technology revenue remains exposed to slower hospital capital spending and longer decision cycles, with a risk that the shift toward leasing could dampen near-term reported growth. Integration of Nevro, while ahead of plan, still carries execution risk, particularly as cost actions intensify and product expansion is contemplated. Macroeconomic or policy headwinds affecting hospital CapEx and reimbursement changes could impact future growth and margin trajectory.

Forward Outlook

For Q4 2025, Globus Medical guided to:

• Continued acceleration in U.S. Spine and international recovery, supported by improved supply chain execution.
• Stronger capital placements in enabling technologies, with Q4 typically the seasonally strongest quarter.

For full-year 2025, management raised guidance:

• Net sales of $2.86 billion to $2.9 billion, up from $2.8 billion to $2.9 billion previously.
• Non-GAAP EPS of $3.75 to $3.85, up from $3.00 to $3.30.

Management highlighted several factors that support confidence in the outlook:

• U.S. Spine and trauma growth trends remain robust into Q4.
• Nevro is now expected to be accretive to earnings in 2025, a year ahead of initial expectations.

Takeaways

Globus Medical’s Q3 results reveal a business leveraging operational scale, disciplined integration, and evolving sales strategies to drive record profitability and cash flow.

• Margin and Cash Flow Strength: Synergy capture, U.S. Spine momentum, and Nevro’s rapid integration underpin the company’s raised outlook and cash generation.
• Strategic Shifts in Capital Sales: The move toward flexible deal structures in enabling tech may create near-term revenue headwinds but positions the business for recurring pull-through and improved customer stickiness.
• Integration and Execution Remain Central: Sustained focus on Nevro integration, trauma portfolio expansion, and international supply chain will be key watchpoints for investors into 2026.

Conclusion

Globus Medical enters Q4 with strong operational momentum, margin expansion, and a more resilient business model. While the company’s pivot in capital sales strategy introduces new revenue dynamics, the underlying execution in core businesses and disciplined capital allocation provide a solid foundation for continued growth and value creation.

Industry Read-Through

Globus Medical’s results highlight several broader industry themes: The shift toward flexible capital acquisition models reflects a wider trend in medtech, as hospital customers increasingly favor leases and operating models over large upfront purchases. Successful integration of acquired businesses, especially in high-margin adjacencies like neuromodulation, is becoming a key differentiator for scale players. Margin expansion through synergy capture and manufacturing optimization is a critical lever as pricing and capital budgets face pressure. Competitors in spine, trauma, and enabling technologies should monitor evolving sales force strategies and capital model transitions, as these will influence both market share and long-term recurring revenue streams across the sector.

GMED Healthcare Medical Devices Spine Integration EBITDA Enabling Technology Trauma